Monographie - Tacrolimus - Stabilis 4.0

Viimeisin päivitys :
19/11/2024

Immunosupressiiviset lääkkeet

Tacrolimus

Oraaliliuos

Injektioneste

Silmätipat

Vakaus lääkevalmisteen

Stabilius seoksissa

Tekijät, jotka vaikuttavat stabiliuteen

Yhteensopivuus

Viitteet

pdf

Kemiallinen rakenne

Oraaliliuos

Viitteet

Oraaliliuos

Viitteet : Tacrolimus

	tyyppi	julkaisu
2436	Lehti	Jacobson PA, Johnson CE, West NJ, Foster JA. Stability of tacrolimus in an extemporaneously compounded oral liquid Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789	Lehti	Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL. Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846	Lehti	Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Pharmazie 2016 71: 185?191.
3946	Lehti	Friciu M, Zaraa S, Leclair G. Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177	Lehti	Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4. Int J Pharm Compound 2018 ;22,6:516-526
4673	Lehti	Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V. Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases. Pharmaceutics 2022 ;14,1:118

Mentions Légales